Ipilimumab Shows Impressive Activity After HSCT Failure

The immunotherapy ipilimumab (Yervoy), showed impressive activity in patients with hematologic malignancies who experienced relapse after receiving a hematopoietic stem cell transplant (HSCT). These patients have limited treatment options and a poor prognosis.

 Medscape Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.